Belén Pequeño

531P Ribociclib treatment patterns and clinical outcomes among women with HR+/HER2- advanced or metastatic breast cancer in Portugal: Final 3-year results from breast cancer lighthouse real-world study

L.I. Pinto, A.L.V. Matos, Belén Pequeño, A.M. Nogal Dias et autres

pt, us, fr (code pays fourni par la source)

The new old breast cancer population in faro Hospital-Algarve Region-Portugal

A. Oliveira, Ricardo Mestre, Belén Pequeño, Isabel Furtado

pt (code pays fourni par la source)

Abstract A275: Co-targeting PIM and PI3K/mTOR pathways with a single molecule: Novel orally available combined PIM/PI3K and PIM/PI3K/mTOR kinase inhibitors.

Carmen Blanco‐Aparicio, Oliver Renner, Elena Gómez‐Casero, Antonio Cebriá et autres

Abstract The PI3K/AKT pathway is commonly activated in human cancer. Multiple small-molecule inhibitors have been developed to target PI3K/mTOR or AKT kinases, but the efficacy of these drugs is compromised by the stimulation of compensatory signaling pathways. The redundancy of oncogenic signaling …

es (code pays fourni par la source)

Abstract B227: Discovery of 3-aryl-3H-[1,2,3]triazolo[4,5-b]pyridin-5-ylamine compounds as potent, selective and orally bioavailable inhibitors of PIM kinases.

Carmen Blanco‐Aparicio, Julen Oyarzábal, Oliver Renner, Rosa M. Álvarez et autres

Abstract The PIM family of serine/threonine kinases (PIM-1, 2 and 3) has been originally identified as proviral integration sites involved in lymphomagenesis induced by murine leukemia virus. In almost all of the MuLV-induced lymphomas in Eμ-Pim-1 transgenic mice either c-MYC or N-MYC …

es (code pays fourni par la source)

Pim 1 kinase inhibitor ETP-45299 suppresses cellular proliferation and synergizes with PI3K inhibition

Carmen Blanco‐Aparicio, Ana Collazo, Julen Oyarzábal, Juan Fernando Martínez-Leal et autres

es (code pays fourni par la source)

Exploring the Gain of Function Contribution of AKT to Mammary Tumorigenesis in Mouse Models

Carmen Blanco‐Aparicio, Marta Cañamero, Yolanda Cecilia, Belén Pequeño et autres

Elevated expression of AKT has been noted in a significant percentage of primary human breast cancers, mainly as a consequence of the PTEN/PI3K pathway deregulation. To investigate the mechanistic basis of the AKT gain of function-dependent mechanisms of breast tumorigenesis, we explored …

es (code pays fourni par la source)

Mice expressing myrAKT1 in the mammary gland develop carcinogen-induced ER-positive mammary tumors that mimic human breast cancer

Carmen Blanco‐Aparicio, Lucía Pérez-Gallego, Belén Pequeño, Juan Fernando Martínez-Leal et autres

AKT1/PKB is a serine/threonine protein kinase that regulates biological processes such as proliferation, apoptosis and growth in a variety of cell types. To assess the oncogenic capability of an activated form of AKT in vivo we have generated several transgenic mouse lines …

es (code pays fourni par la source)

Inhibition of phosphatidylinositol-3-kinase synergizes with gemcitabine in low-passage tumor cell lines correlating with Bax translocation to the mitochondria

Carmen Blanco‐Aparicio, Belén Pequeño, Victoria Moneo, Lourdes Romero et autres

Apoptotic pathways, including the phosphatidylinositol-3-kinase (PI3K)/AKT survival pathway, are altered in most cancer cells in relation to their normal counterparts and these differences may present an excellent therapeutic window. To gain insight into the relevance of the PI3K pathway as a target …

es (code pays fourni par la source)